Races of small molecule clinical trials for the treatment of COVID‐19: An up‐to‐date comprehensive review
Suwen HuCollaborative Innovation Center of Chinese Medicines from Zhejiang Province Hangzhou Normal Umiversity Hangzhou ChinaSongwei JiangCollaborative Innovation Center of Chinese Medicines from Zhejiang Province Hangzhou Normal Umiversity Hangzhou ChinaQi XiangCollaborative Innovation Center of Chinese Medicines from Zhejiang Province Hangzhou Normal Umiversity Hangzhou ChinaRenren BaiCollaborative Innovation Center of Chinese Medicines from Zhejiang Province Hangzhou Normal Umiversity Hangzhou ChinaXiang‐Yang YeCollaborative Innovation Center of Chinese Medicines from Zhejiang Province Hangzhou Normal Umiversity Hangzhou ChinaTian XieCollaborative Innovation Center of Chinese Medicines from Zhejiang Province Hangzhou Normal Umiversity Hangzhou China
2021en
ABI
Аннотация
The coronavirus disease-19 (COVID-19) pandemic has become a global threat since its first outbreak at the end of 2019. Several review articles have been published recently, focusing on the aspects of target biology, drug repurposing, and mechanisms of action (MOAs) for potential treatment. This review gathers all small molecules currently in active clinical trials, categorizes them into six sub-classes, and summarizes their clinical progress. The aim is to provide the researchers from both pharmaceutical industries and academic institutes with the handful information and dataset to accelerate their research programs in searching effective small molecule therapy for treatment of COVID-19.
Перевод пока недоступен
Идентификаторы
Цитирования и источники
Цитирований: 2Использованных источников: 0